The Retrospective Study of MUC1-targeted Dendritic Cell-based Vaccine in Patients with Refractory Non-small Cell Lung Cancer

The Retrospective Study of MUC1-targeted Dendritic Cell-based Vaccine in Patients with Refractory Non-small Cell Lung Cancer - MUC1-targeted Dendritic Cell-based Vaccine in Patients with Refractory Non-small Cell Lung Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021866

Enrollment

Registered

2016-04-12

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Between August 2005 and May 2015, NSCLC patients who were treated with MUC1-targeted dendritic cell-based vaccines as an advanced medical treatment approved by the Ministry of Health, Labor and Welfare, Japan, in Shiga University of Medical Science Hospital.

Exclusion criteria

Exclusion criteria: Patients with NSCLC that was not refractory for some standard cancer treatments.

Design outcomes

Primary

Measure	Time frame
Efficacy (Overall survival from the initial vaccination)	—

Secondary

Measure	Time frame
Safety(Incidence and grade of adverse events) Anti-tumor effect after the six vaccinations Immunological responses after the six vaccinations (MUC1-specific cytotoxicity and frequency of regulatory T cells in peripheral blood)	—

Countries

Japan

Contacts

Public ContactKoji Teramoto

Shiga University of Medical Science Department of Medical Oncology

teramoto@belle.shiga-med.ac.jp077-548-3590

Outcome results